Enter your ZIP code:

Please enter a 5 digit zipcode
No results...

Entering your zip code helps us to provide information and results that are more relevant to you.

Your privacy is important to us. By continuing, you agree to our Privacy Policy.





A Multicenter, Randomized, Open-label, Phase II Study of [177lu]lu-dotatate in Adults with Progressive Intracranial Grade 1-3 Meningioma

Cancer
Daniela Bota
Brain and Nervous System

Study Description

This is an open-label, multicenter, randomized, phase 2 clinical study to evaluate the efficacy of [177Lu]Lu-DOTA-TATE (177Lu-Dotatate) in patients with progressive grade 1-3 intracranial meningioma.

Eligibility

Adult patients with progressive WHO grade 1-3 meningioma

A female nurse attentively holds a tablet, ready to assist with patient care and medical information.

Interested in Participating in this Trial?

Thank you for your interest with our team.

One of our specialists will be in contact with you soon.